1. Home
  2. AUROW vs TGTX Comparison

AUROW vs TGTX Comparison

Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Innovation Inc. Warrant

AUROW

Aurora Innovation Inc. Warrant

HOLD

Current Price

$0.32

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$53.22

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUROW
TGTX
Founded
2017
1993
Country
United States
United States
Employees
1900
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
6.0B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AUROW
TGTX
Price
$0.32
$53.22
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$49.80
AVG Volume (30 Days)
37.2K
2.0M
Earning Date
04-30-2025
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
N/A
$26.69
P/E Ratio
N/A
$432.04
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$25.37
52 Week High
$1.08
$53.98

Technical Indicators

Market Signals
Indicator
AUROW
TGTX
Relative Strength Index (RSI) 43.17 82.92
Support Level $0.17 $28.57
Resistance Level $0.42 N/A
Average True Range (ATR) 0.08 2.43
MACD -0.02 1.13
Stochastic Oscillator 4.94 95.68

Price Performance

Historical Comparison
AUROW
TGTX

About AUROW Aurora Innovation Inc. Warrant

Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Share on Social Networks: